Camurus AB (SE:CAMX)
:CAMX
Sweden Market
Advertisement

Camurus AB (CAMX) Earnings Dates, Call Summary & Reports

Compare
3 Followers

Earnings Data

Report Date
Feb 12, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
2.04
Last Year’s EPS
2.45
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with both significant achievements and notable challenges. Camurus showed strong revenue growth, profitability, and positive R&D developments, but faced hurdles with lowered revenue guidance, slowed Buvidal sales, and funding issues in the U.K. market.
Company Guidance
During Camurus' Q3 2025 earnings call, CEO Fredrik Tiberg highlighted strong financial performance, with quarterly revenues rising by 18% year-on-year to SEK 575 million, driven by significant Brixadi royalties. Despite facing funding challenges affecting Buvidal sales in Europe, particularly in the UK, Brixadi experienced double-digit sales growth quarter-to-quarter. Profitability remained robust, with a 48% growth to SEK 245 million, and the cash position increased to SEK 3.5 billion. The company maintained its profit guidance but adjusted its full-year revenue outlook due to underperformance in U.S. Brixadi revenues. Camurus also advanced its R&D pipeline, securing two new orphan drug designations for CAM2029 and completing a Phase Ib trial for CAM2056. The company is preparing for the European launch of Oczyesa and aligning its U.S. expansion plans with the expected approval timeline for Oclaiz.
Significant Revenue Growth
Camurus reported SEK 567 million in revenue for the quarter, reflecting an 8% increase compared to the same period last year, with year-to-date revenue growth of 37%.
Strong Profitability
The company's profit before tax was SEK 245 million, representing a 43% profit margin in the quarter and a 48% increase in profit compared to the same period last year.
Brixadi Sales Surge
Brixadi sales in the U.S. generated SEK 111 million in royalty income for the quarter, up 91% compared to the same period last year and a 25% increase from the previous quarter.
Positive R&D Developments
Marketing approvals for Oczyesa were received in the U.K., and Camurus was granted 2 new orphan drug designations of CAM2029 in autosomal dominant polycystic kidney disease.
Cash Position Improvement
Camurus increased its cash position by SEK 167 million, resulting in a net cash position of SEK 3.5 billion, which is an increase of 28% compared to last year.

Camurus AB (SE:CAMX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SE:CAMX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 12, 2026
2025 (Q4)
2.04 / -
2.45
Nov 06, 2025
2025 (Q3)
3.30 / 3.27
2.1651.39% (+1.11)
Jul 17, 2025
2025 (Q2)
3.42 / 4.08
1.25226.40% (+2.83)
May 15, 2025
2025 (Q1)
2.92 / 3.35
1.36146.32% (+1.99)
Feb 13, 2025
2024 (Q4)
1.86 / 2.45
-0.271007.41% (+2.72)
Nov 07, 2024
2024 (Q3)
1.56 / 2.16
1.544.00% (+0.66)
Jul 16, 2024
2024 (Q2)
1.47 / 1.25
5.42-76.94% (-4.17)
May 08, 2024
2024 (Q1)
1.09 / 1.36
1.02332.94% (+0.34)
Feb 15, 2024
2023 (Q4)
-1.75 / -0.27
0.23-217.39% (-0.50)
Nov 09, 2023
2023 (Q3)
0.71 / 1.50
0.63138.10% (+0.87)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

SE:CAMX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
kr588.50kr554.00-5.86%
Jul 17, 2025
kr690.00kr694.00+0.58%
May 15, 2025
kr621.50kr543.50-12.55%
Feb 13, 2025
kr586.50kr610.00+4.01%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Camurus AB (SE:CAMX) report earnings?
Camurus AB (SE:CAMX) is schdueled to report earning on Feb 12, 2026, TBA (Confirmed).
    What is Camurus AB (SE:CAMX) earnings time?
    Camurus AB (SE:CAMX) earnings time is at Feb 12, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Camurus AB stock?
          The P/E ratio of Camurus AB is N/A.
            What is SE:CAMX EPS forecast?
            SE:CAMX EPS forecast for the fiscal quarter 2025 (Q4) is 2.04.
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis